BERMUDA-BUSINESS
17.1.2023 22:27:35 CET | Business Wire | Press release
The second annual Bermuda Risk Summit, presented by the Bermuda Business Development Agency (BDA), in partnership with the Association of Bermuda Insurers and Reinsurers (ABIR) and EY, will begin on March 6 with a keynote conversation with Bermuda’s Premier, The Hon. David Burt, JP, MP, followed by a group CEO panel.
Sophie Roberts, Head of The Insurer TV, will moderate the opening panel featuring Peter Bell, CEO & Managing Director, Everest Re, Stephen Catlin, Executive Chairman, Convex (Past Chair & Deputy Chair ABIR), Christopher Schaper, CEO, AIG Re (ABIR Deputy Chair), and Megan Thomas, CEO, Hamilton Re.
David Hart, CEO, BDA said, “The BDA is so pleased to be able to once again present this flagship event, which showcases the entire breadth and depth of the world’s risk capital. The Bermuda Risk Summit creates both long-term business development growth potential, in terms of deal making opportunities around the event in front of an extremely important June 1 renewal season, as well as, the immediate economic impacts of attracting business travelers to Bermuda that week.”
The immediate economic impact of last year’s event, which had 350 delegates (80 from overseas), including lodging, transportation, food and beverage, retail, and recreation, was estimated at over one million dollars, and supported around 200 jobs. This figure does not include the additional visitors who flew to Bermuda for business meetings around the event. The BDA anticipates an even stronger attendance level this year, as we continue to assist with building out Bermuda’s globally significant risk and insurance sector and showcasing Bermuda’s strengths.
Potential registrants are strongly encouraged to act soon to receive the early bird registration price, of $395, ending next Friday, 27 January. Included in the early bird price are keynote breakfasts, networking breaks and lunches at Hamilton Princess Hotel, an evening seaside soiree at the Hamilton Beach Club and an island lunch cruise. Visit our event webpage to register.
Overseas guests should also act before Friday, February 3 to secure special hotel room rates. After February 3, hotel room prices will increase significantly, or be completely sold out, due to limited availability. To book your room please call 1-441-295-3000 or the Global Reservations Centre on 1-800441-1414. Alternatively, click here to reserve your room online. Please use booking code: ‘Bermuda Risk’ to take advantage of the preferred rate.
In terms of sponsorships, the BDA is pleased to announce that Hyperexponential have come on board as a diamond sponsor, SS&C is a gold sponsor, AM Best and Kirkland & Ellis are silver sponsors, Demotech is WIFI sponsor, and The Insurer is our official media partner. Other sponsorship opportunities are still available. Please e-mail bermudarisk@bda.bm if you wish to participate.
The overall theme of the 2023 Bermuda Risk Summit, being held from March 6-8, is ‘Innovation, Sustainability and Collaboration.
Speakers confirmed to date include Suzanne Williams Charles, Director of Policy and Regulation, ABIR will moderate a panel of international regulators featuring Chlora Lindley-Myers, President, National Association of Insurance Commissioners and Gerald Gakundi, Director, Supervision (Insurance), Bermuda Monetary Authority.
Craig Redcliffe, Partner, EY will moderate an ‘Evolution of Partner Capital’ panel featuring Jasmine Desilva, SVP ILS, Artex Capital Solutions, Julia Henderson, Chief Commercial Officer, Vesttoo, and Sylvie Werther, Director of Operations/Reinsurance, Nephila Capital.
Joseph Petrelli, President, Demotech and Todd Kozikowski, President, 44North, LLC, will present their findings on Florida’s disparate litigation levels.
A panel discussing investor’s experiences of Bermuda will feature, Scott Frederick, Managing Partner, Sands Capital Ventures, Adrian Jones, Managing Director, Re/Insurance and Partner, HSCM Ventures, and Armin Rothauser, Senior Partner, Castlelake Investments.
Peter Giacone, Global Head of Insurance, KBRA, Stefan Holzberger, Chief Rating Officer, AM Best, and Joseph Petrelli, President, Demotech will speak on a panel entitled ‘Global Financing Conditions - A Rating Agency Discussion.’
Kerr Kennedy, Associate Partner, EY, will moderate Yosha Delong, Global Head of Cyber, Mosaic Insurance, Noel Pearman, SVP, Cyber Product Line Leader, AXA XL, Sebastien Plummer, Cyber Specialist Broker, Gallagher Re, and Edouard Von Heberstein, CEO Spectra who will explore the future of cyber reinsurance.
Saadia Savory, Vice President, Excess Casualty, Aspen, and Shannon Totten, SVP, Casualty Insurance Practice Leader Bermuda, Sompo International, will discuss Bermuda’s vibrant casualty lines of business.
Chris Hayward, Chief Underwriting Officer, MS Amlin Reinsurance, Mark Wheeler, Co-Chief Executive Officer & Director, Mosiac and Kostya Zolotusky, CEO, Itasca Re will explore diverse specialty lines of business.
And last but certainly not least, founder, chairman and CEO of SS&C, William C. Stone, will speak about innovative technology with Alex Huang, Chief Risk Officer, Sun Life International.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117006105/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom